Interleucina-2 no tratamento adjuvante de paciente com linfocitopenia CD4 idiopática e tuberculose disseminada
Interleukin 2 as adjuvant treatment in a patient with idiopathic CD4 lymphocytopenia and disseminated tuberculosis
Juliana Fóes Bianchini Garcia; Nathalia Silveira Barsotti; Cristina Maria Kokron; Jorge Kalil; Pedro Giavina-Bianchi
Resumo
Linfocitopenia CD4 idiopática (LCI) é uma imunodeficiência rara e grave caracterizada por uma diminuição inexplicável da contagem absoluta de linfócitos T CD4, a qual está associada a infecções oportunistas. Existem poucos relatos de casos na literatura que descrevem a IL2 como uma opção terapêutica em infecções oportunistas associadas à LCI. Relatamos os benefícios da adição de IL2 ao tratamento padrão em um paciente com ICL e infecções oportunistas. Um homem de 38 anos de idade foi internado por acidente vascular cerebral isquêmico devido à vasculite infecciosa. A análise do líquido cefalorraquidiano mostrou meningite neutrofílica. Cultura e PCR foram positivos para Mycobacterium tuberculosis. A tomografia de tórax foi compatível com tuberculose pulmonar. O paciente também apresentava candidíase oral, onicomicose e dermatite seborreica. A contagem de células sanguíneas mostrou linfocitopenia. O tratamento padronizado para tuberculose disseminada (RIPE) e fluconazol foram iniciados e mantidos em casa após a alta do paciente. Após cinco meses de seguimento, o paciente foi encaminhado ao imunologista clínico, pois não apresentava melhora clínica significativa, tendo sido hospitalizado diversas vezes. A avaliação imunológica mostrou uma contagem sanguínea de CD4 T consistentemente inferior a 100 células/mm3 e o diagnóstico de LCI foi confirmado (linfocitopenia inexplicável com menos de 300 células/mm3 ou menos de 20% de células T CD4+ em mais de uma ocasião com pelo menos 2 meses de intervalo). O paciente também apresentava episódios raros de linfocitopenia de células B e hipogamaglobulinemia, tendo recebido gamaglobulina. Como tratamento adjuvante, a IL2 subcutânea foi associada ao tratamento padronizado. Até agora, o paciente recebeu cinco ciclos consecutivos de IL2, mostrando melhora clínica e aumento da contagem de células T CD4 no sangue, atingindo um valor máximo de 401 células/mm3. As células CD8, B e natural killer também aumentaram. Novas análises do líquido cefalorraquidiano foram normais, e a cultura de Mycobacterium tuberculosis e a PCR foram negativas. Nosso paciente com infecções oportunistas associadas à LCI apresentou evolução laboratorial e clínica favoráveis após a adição de IL2 ao tratamento padrão. Este relato de caso apoia o uso de IL2 como um coadjuvante seguro e potencialmente eficaz para infecções oportunistas associadas à LCI. O caso destaca a importância da avaliação e acompanhamento de pacientes com suspeita de imunodeficiência por imunoalergologistas.
Palavras-chave
Abstract
Idiopathic CD4 T lymphocytopenia (ICL) is a rare and severe immunodeficiency disorder characterized by an unexplained decrease of absolute CD4 T-lymphocyte cell counts, which is associated with opportunistic infections. There are few case reports in the literature describing the use of interleukin 2 (IL2) as a therapeutic option in ICL-associated opportunistic infections. We report the benefits of adding IL2 to the standard treatment in a patient with ICL and opportunistic infections. A 38-year-old male patient was admitted with ischemic stroke due to infectious vasculitis. Cerebrospinal fluid analysis revealed neutrophilic meningitis. Culture and PCR were positive for Mycobacterium tuberculosis. Chest CT was compatible with pulmonary tuberculosis. The patient also presented oral candidiasis, onychomycosis, and seborrheic dermatitis. Blood cell count revealed lymphocytopenia. Standardized treatment for disseminated tuberculosis (RIPE therapy) and fluconazole were initiated and maintained at home after the patient's discharge. After five months of follow-up, the patient was referred to a clinical immunologist, due to the absence of significant clinical improvement, with multiple hospitalizations over the follow-up period. Immunological assessment showed CD4 T cell counts consistently below 100 cells/mm3, and the diagnosis of ICL was confirmed (unexplained lymphocytopenia with less than 300 cells/mm3 or less than 20% of CD4+ T cells on more than one occasion at least 2 months apart). The patient also presented rare episodes of B cell lymphocytopenia and hypogammaglobulinemia, treated with gammaglobulin. As an adjuvant treatment, subcutaneous IL2 was added to the standard treatment. So far the patient underwent five consecutive cycles of IL2, showing clinical improvement and increased CD4 T cell counts, reaching a maximum value of 401 cells/mm3. CD8, B and natural killer cells also increased. New cerebrospinal fluid analyses were normal, and new Mycobacterium tuberculosis culture and PCR were negative. Our patient had opportunistic infections associated with ICL and presented favorable laboratory and clinical outcomes after the association of IL2 to the standard treatment. This case report supports the use of IL2 as a safe and potentially effective adjuvant treatment for ICL-associated opportunistic infections. The case highlights the importance of immunological assessment and follow-up of patients with suspected immunodeficiency.
Keywords
References
1. Unexplained CD4+ T-lymphocyte depletion in persons without evident HIV infection - United States. MMWR. 1992;41:541.
2. Laurence J, Siegal FP, Schattner E, Gelman IH, Morse S. Acquired immunodeficiency without evidence of infection with human immunodeficiency virus types 1 and 2. Lancet. 1992;340:273-4.
3. Smith DK, Neal JJ, Holmberg SD. Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-lymphocytopenia Task Force. N Engl J Med. 1993;328:373.
4. Ho DD, Cao Y, Zhu T, et al. IdiopathicCD4+ T lymphopenia(ICL): immunodeficiency without evidence of human immunodeficiency virus infection. N Engl J Med. 1993;328:380-6.
5. Spira TJ, Jones BM, Nicholson JKA, et al. Idiopathic CD4+ T lymphocytopenia – an analysis of five patients with unexplained opportunistic infections. N Engl J Med. 1993;328:86-92.
6. Duncan RA, Von Reyn CF, Alliegro GM, Toossi Z, Sugar AM, Levitz SM. Idiopathic CD4+ T lymphocytopenia – four patients with opportunistic infections and no evidence of HIV infection. N Engl J Med. 1993;328:393-8.
7. Aledort LM, Operskalski EA, Dietrich SL, et al. CD4+ counts in a study of transfusion safety. N Engl J Med. 1993;328:441-2.
8. Zonios DI, Falloon J, Bennett JE, et al. CD4+ lymphocytopenia: natural history and prognostic factors. Blood. 2008;112:287-94.
9. DeHovitz JA, Feldman J, Landesman S. Idiopathic CD4+ T-lymphocytopenia. N Engl J Med. 1993;329:1045-6.
10. Petrofsky M, Bermudez LE. CD4+ T cells but not CD8+ or gd+ lymphocytes are required for host protection against Mycobacterium avium infection and dissemination through the intestinal route. Infect Immun. 2005;73:2621-7.
11. Shiratsuchi H, Krukovets I, Ellner JJ. Role of T cell subsets in the modulation of Mycobacterium avium growth within human monocytes. Cell Immunol. 2000;202:6-12.
12. Cunningham-Rundles C, Murray HW, Smith JP. Treatment of idiopathic CD4 T lymphocytopenia with IL-2. Clin Exp Immunol. 1999;116:322-5.
13. Warnatz K, Draeger R, Schlesier M, Peter HH. Successful IL-2 therapy for relapsing herpes zoster infection in a patient with idio- pathic CD4+ T lymphocytopenia. Immunobiology. 2000;202:204‑11.
14. Wilhelm M, Weissinger F, Kunzmann V, Muller JG, Fahey JL. Idiopathic CD4+ T cell lymphocytopenia evolving to monoclonal immunoglobulins and progressive renal damage responsive to IL-2 therapy. Clin Immunol. 2001;99:298-04.
15. Yilmaz-Demirdag Y, Wilson B, Lowery-Nordberg M, Bocchini JA, Bahna SL. Interleukin-2 treatment for persistent cryptococcal meningitis in a child with idiopathic CD4(+) T lymphocytopenia. Allergy Asthma Proc. 2008;29:421-4.
16. Gorlin R, Gelb B, Diaz GA, Lofsness KG, Pittelkow MR, Fenyk JR. WHIM syndrome, an autosomal dominant disorder: clinical, hematological, and molecular studies. Am J Med Genet. 2000;91:368‑76.
17. Ozsahin H, Arredondo-Vega FX, Santisteban I, et al. Deaminase deficiency in adults. Blood. 1997;89:2849-55.
18. Shovlin CL, Simmonds HA, Fairbanks LD, et al. Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency. J Immunol. 1994;153:2331.
19. Ostergaard PA, Deding A, Eriksen J, Mejer J. Common variable immunodeficiency and purine nucleotidase and nucleoside phosphorylase deficiency. A case report. Acta Pathol Microbiol Scand. 1980;88:299-302.
20. Gatti RA, Boder E, Good RA. Immunodeficiency, radiosensitivity, and the XCIND syndrome. Immunol Res. 2007;38:87-101.
21. Paganelli R, Scala E, Scarselli E, et al. Selective deficiency of CD4+/ CD45RA+ lymphocytes in patients with ataxia-telangiectasia. J Clin Immunol. 1992;12:84-91.
22. Michałkiewicz J, Barth C, Chrzanowska K, Gregorek H, Syczewska M, Weemaes CMB, et al. Abnormalities in the T and natural killer lymphocyte phenotype in patients with Nijmegen breakage syndrome. Clin Exp Immunol. 2003; 134:482-90.
23. Schubert R, Reichenbach J, Zielen S. Deficiencies in CD4+ and CD8+ T cell subsets in ataxia telangiectasia. Clin Exp Immunol. 2002;129:125-32.
24. Mitsuyasu R, Gelman R, Weng Cherng D, et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent anti- retroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clini- cal trial – AIDS Clinical Trials Group 328. Arch Intern Med. 2007;167:597‑605.
25. Marchetti G, Meroni L, Varchetta S, et al. Low dose prolonged intermittent interleukin 2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis. 2002;186:606-16.
26. Emery S, Capra WB, Cooper DA, et al. Pooled analysis of 3 randomized, controlled trials of interleukin 2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis. 2000;182:428‑34.
27. Jacobson EL, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA. 1996;93:10405-10.
28. Katz P, Yeager H Jr, Whalen G, Evans M, Swartz RP, Roecklein J. Natural killer cell-mediated lysis of Mycobacterium-avium complexinfected monocytes. J Clin Immunol. 1990;10:71-7.
29. Reza G, Pezzofti P, Aiuti F. Acquired immunodeficiency without HIV infection: epidemiology and clinical outcome in Italy. BMJ. 1995;311:785-6.
30. Netea MG, Brouwer AE, Hoogendoorn EH, Van der Meer JW, Koolen M, Verweij PE, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon-gamma therapy. Clin Infect Dis. 2004;39:e83-7.
31. Cunningham-Rundles C, Murray HW, Smith JP. Treatment of idiopathic CD4 T lymphocytopenia with IL-2. Clin Exp Immunol. 1999;116:322-5.
32. Trojan T, Collins R, Khan D. A. Safety and efficacy of treatment using interleukin-2 in a patient with idiopatic CD4 lymphopenia and Mycobacterium avium-intracellulare. Clin Exp Immunol. 2009;156:440-5.
33. Sternfeld T, Nigg A, Belohradsky BH, Bogner JR. Treatment of relapsing Mycobacterium avium infection with interferom-gamma and interleukin-2 in an HIV-negative patient with low CD4 syndrome. J Infect Dis. 2010;14S:e198-201.
34. Shen H, Min R, Tan Q, et al. The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis. Arch Med Sci. 2015;11:584-90.
Submitted date:
01/10/2017
Accepted date:
02/15/2017
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email